Skip to main content

Branded

  • FDA approves oral suspension of Eisai’s Fycompa

    SILVER SPRING, Md. — The Food and Drug Administration has approved Eisai’s Fycompa (perampanel) oral suspension, the company announced Monday. The oral suspension has been approved to treat partial-onset seizures with or without secondary generalized seizures, as well as for primary generalized tonic-clinic (PGTC) seizures in patients with epilepsy older than 12. 
     

  • FDA approves first drug for Parkinson’s-related hallucinations, delusions

    SILVER SPRING, Md. — The Food and Drug Administration recently approved a new drug that treats delusions and hallucinations that are associated with psychosis affecting patients with Parkinson’s disease. 
     
    Nuplazid (pimavanserin), from Acadia Pharmaceuticals, is the first medication to be approved to treat Parkinson’s-related psychosis, which affects some 40% of the 4-6 million patients with Parkinson’s disease. The drug was granted breakthrough therapy designation and a priority review by the FDA. 

  • FDA expands indication for Teva’s ProAir RespiClick

     
    SILVER SPRING, Md. — The Food and Drug Administration on Friday approved Teva’s ProAir RespiClick (albuterol sulfate) inhalation powder to treat or prevent bronchospasm in children aged 4 to 11 years. The drug had previously been approved for the same indication in patients older than 12. 
     
    The drug is the only breath-activated multi-dose short-acting beta agonist, inhaler in the U.S., Teva said. 
     

  • Arizona, Texas top Walgreens Flu Index 'most active' list for 2015/2016 season

    DEERFIELD, Ill. - With flu activity winding down in the U.S., Walgreens on Friday announced the top markets and states for flu activity for the season, according to its season-ending Walgreens Flu Index examining aggregate prescription data from Nov. 2015 through mid-April 2016.
     
    The states with the highest rates of influenza, according to the Index, were Arizona, Texas, Kentucky, Mississippi and Tennessee.
     

  • Takeda expands patient assistance program in U.S.

    DEERFIELD, Ill. — Takeda Pharmaceuticals on Thursday announced that it would be expanding its Help At Hand patient assistance program for patients in the United States. 
     
    The expansion will allow patients whose income is at 400% of the federal poverty level to apply for discounted or no-cost medicine under the program, which currently includes 11 of the company’s drugs. Under the expansion, a family of four whose household income is about $100,000 is now eligible for the prescription drug program. 
     

  • Lupin re-introduces Methergine tablets

    BALTIMORE — Lupin on Thursday announced that it would be re-introducing its Methergine (methylergonovine maleate) tablets. The drug is indicated to manage uterine atony, hemorrhage and subinvolution of the uterus following delivery of the placenta, and for control of uterine hemorrhage in the second stage of labor. It's also the preferred treatment for postpartum hemorrhage, according to American Congress of Obstetricians and Gynecologists (ACOG) guidelines. 
     

  • AbbVie grows oncology pipeline with Stemcentrx acquisition

    NORTH CHICAGO — Biopharmaceutical company AbbVie on Thursday announced its planned acquisition of Stemcentrx and its late-stage potential treatment for small cell lung cancer, Rova-T (rovalpituzumab tesirine). 
     

  • FDA approves Exelixis’ Cabometyx

    SILVER SPRING, Md. — The Food and Drug Administration has approved Exelixis’ Cabometyx (cabozantinib) tablets, the company announced this week. Cabometyx is indicated to treat patients with advanced renal cell carcinoma who have previously received anti-angiogenic treatment. 
     
X
This ad will auto-close in 10 seconds